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Côte d’Ivoire
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Abidjan, Côte d’Ivoire, 2 Programme National de Lutte contre les Maladies Tropicales Négligées à
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Nature, Université Nangui Abrogoua Abidjan, Abidjan, Côte d’Ivoire, 5 Division of Biostatistics, Washington
University School of Medicine, St. Louis, Missouri, United States of America, 6 Infectious Diseases Division,
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of
America
* Pufischer@wustl.edu

OPEN ACCESS
Citation: Loukouri A, Méité A, Koudou BG, Goss
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Abstract
Mass Drug Administration (MDA) programs to eliminate Lymphatic Filariasis (LF) in western
Africa use the anthelminthics ivermectin plus albendazole. These drugs have the potential
to impact also Soil-Transmitted Helminth (STH) infections, since the drugs have a broad
range of anthelminthic activity. Integration of preventive chemotherapy efforts for LF, onchocerciasis and STH is recommended by the World Health Organization (WHO) in order to
avoid duplication of MDA and to reduce costs. The objective of the current study was to
determine whether five semi-annual rounds of community-wide MDA to eliminate LF and
onchocerciasis have a greater impact on STH than three annual rounds of MDA with similar
compliance. The effects of MDA using ivermectin (IVM, 0.2 mg/kg) combined with albendazole (ALB, 400 mg) on the prevalence and intensity of hookworm infection were evaluated in
the Abengourou (annual MDA) and Akoupé (semi-annual MDA) health Districts in eastern
Côte d’Ivoire from 2014 to 2017. A cross-sectional approach was used together with mixed
logistic regression, and mixed linear models. Subjects were tested for STH using the KatoKatz technique before the first round of MDA and 12, 24, and 36 months after the first round
of MDA. The mean self-reported MDA compliance assessed during the survey was 65%,
and no difference was observed between treatment areas. These results were confirmed by
an independent coverage survey as recommended by WHO. Hookworm was the most prevalent STH species in both areas (23.9% vs 12.4%) and the prevalence of other STH species
was less than 1%. The crude prevalence of hookworm dropped significantly, from 23.9% to
5.5% (p <0.001, 77% reduction) in the annual MDA treatment area and from 12.4% to 1.9%
(p <0.001, 85% reduction) in the semi-annual treatment area. The average intensity of hookworm infection decreased in the annual MDA area (406.2 epg to 118.3 epg), but not in the
semi-annual MDA area (804.9 epg to 875.0 epg). Moderate and heavy infections (1% and
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1.3% at baseline) were reduced to 0% and 0.4% in the annual and semi-annual treatment
areas, respectively. Using a mixed logistic regression model, and after adjusting for baseline
prevalence, only the year 2 re-examination showed a difference in prevalence between
treatments (OR: 2.26 [95% CI: 1.03, 4.98], p = 0.043). Analysis of intensity of hookworm
infection indicated also that treatment differences varied by follow-up visit. In conclusion
twelve months after the last treatment cycle, three annual and five semi-annual rounds of
community-wide MDA with the combination of IVM and ALB showed strong, but similar
impact on hookworm prevalence and intensity in eastern Côte d’Ivoire. Therefore, an annual
MDA regimen seems to be an efficient strategy to control hookworm infection in endemic
areas with low and moderate infection prevalence.
Trial registration: The study was registered at ClinicalTrial.gov under the number
NTC02032043.

Author summary
Community-wide MDA to eliminate LF and onchocerciasis has the beneficial effect to
reduce also STH infections. The objective of the current study was to determine whether
five semi-annual rounds of MDA have a greater impact on STH than three annual rounds
of MDA using ivermectin combined with albendazole. In Abengourou and Akoupé health
Districts in eastern Côte d’Ivoire the prevalence and intensity of hookworm infection
were evaluated before and after MDA. Prior to MDA and after each annual treatment
cycle, study participants were tested for STH using the Kato-Katz technique. The mean
MDA compliance assessed during the survey was 65%, and no difference was observed
between treatment areas. Compliance results were confirmed by an independent coverage
survey as recommended by WHO. Hookworm was the most prevalent STH species in
both areas and the prevalence of other STH species was less than 1%. The crude prevalence of hookworm dropped significantly, from 23.9% to 5.5% in the annual and from
12.4% to 1.9% in the semi-annual treatment areas. The intensity of hookworm infection
in infected persons decreased significantly in the annual MDA area (406.2 epg to 118.3
epg, p = 0.017), but not in the semi-annual MDA area (804.9 epg to 875.0 epg, p = 0.216).
Moderate and heavy infections were reduced to less than 1% in both treatment areas.
Three annual and five semi-annual rounds of community-wide MDA with the combination of IVM and ALB showed strong, but similar effects on hookworm prevalence and
intensity in eastern Côte d’Ivoire. Therefore, an annual MDA regimen seems to be an efficient strategy for controlling hookworm infection in endemic areas with low and moderate infection prevalence.

Introduction
Soil-Transmitted Helminth (STH) infections are one of the most common Neglected Tropical
Diseases (NTDs) and cause significant public health problems in many poor communities
located in tropical and sub-tropical countries [1]. Approximately 1.5 billion people are infected
with at least one STH species [2], and more than 300 million show clinical signs including:
pneumonitis referred to as Loeffler’s syndrome [3], intestinal obstruction [4], anemia [5],
abdominal colitis and pain, diarrhea, dysentery associated with rectal prolapse, malnutrition,
stunted growth [6] and long-term disability or early death.
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Resolutions of the World Health Organization (WHO) call for intensified control of STH,
and this is supported by pharmaceutical companies, international aid agencies and philanthropic organizations [7, 8]. The WHO focuses on the most vulnerable populations such as
pre-school children, school-aged children and women of child-bearing age. It calls for regular
deworming to avert widespread morbidity and reduce the occurrence, extent, severity and
long-term consequences of morbidity, and reduce transmission [9]. Twice yearly Mass Drug
Administration (MDA) of the target population using the anthelminthics albendazole (ALB)
or mebendazole (MEB) is recommended in high risk communities (prevalence �50%) and
annual MDA is recommended for low risk communities (20% � prevalence <50%) [7]. Unlike
for the elimination of lymphatic filariasis (LF) and onchocerciasis WHO does not recommend
community-wide MDA for STH at present.
Large parts of Sub-Saharan Africa are not only endemic for STH but also for LF and onchocerciasis. A key intervention strategy to eliminate LF and onchocerciasis is MDA using ivermectin (IVM) alone (for onchocerciasis) or IVM combined with ALB (for LF). This strategy is
directed at the entire population at risk of infection aged 5 years or older [10]. Both drugs have
a broad range of anthelminthic activity and are also effective against STH [11, 12]. The combination of IVM and ALB has higher cure and egg reduction rates for STH compared to a single
dose of either ALB, MEB or IVM [13]. MDA using IVM plus ALB to the entire community
reduce STH transmission, because of its effect on the parasite reservoir. This is especially true
for hookworm, because adults serve as a major reservoir for that infection [14]. Twice-yearly
community MDA might lead to further reductions in parasite intensity and infection prevalence. This will support the ambitious goal of WHO to control morbidity, and eventually
break transmission of STH [8]. Integration of STH intervention with LF and/or onchocerciasis
elimination programs prevents unnecessary duplication of MDA, thus reducing costs [7, 15].
Like other countries in West Africa, Côte d’Ivoire is endemic for STH [16–18]. Since the
early 2000s school-based deworming for STH was linked with the polio vaccination campaign,
the vitamin A distribution program, the World Food Program (WFP) [8], and in selected
areas with the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE)
project [19]. The MDA scheduled for school-aged children varied based on the epidemiological status in the target population and the availability of financial resources. Although specific
funds were available for community-wide MDAs to treat schistosomiasis, onchocerciasis and
LF, no specific funds for STH control were available in Côte d’Ivoire during our study. Therefore, in areas where STH are not co-endemic with onchocerciasis or LF, no MDA for the control of STH was performed.
The health Districts of Abengourou and Akoupé, in the eastern Departments of Côte d’Ivoire
are co-endemic for LF, onchocerciasis and STH. Prior to 2009, several rounds of annual IVM
(Community Directed Treatment with IVM, CDTi) were provided for onchocerciasis control
to smaller villages (� 3000 residents) within a radius of 5 miles of a river. Abengourou and
Akoupé health Districts were targeted by the national LF elimination program to receive MDA
using IVM plus ALB. This MDA was initiated in 2014 in parallel with the start of the present
study. This study compared the impact of annual (3 rounds) and semi-annual MDA (5 rounds)
on hookworm, the most prevalent STH species. We used a cross-sectional approach (S1 Strobe
checklist) to assess differences in drug coverage and hookworm intensity and prevalence.

Methods
Ethical approval and selection of study areas
This study received ethical clearance from institutional review boards at Washington University School of Medicine (St. Louis, MO) and at the National Committee of Ethics and Research
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of Côte d’Ivoire (CNER/797/Ti/15). The study was registered at ClinicalTrial.gov under the
number NTC02032043. The administrative and village authorities were informed about the
procedures, benefits and potential risks of the project. Oral informed consent from each participant in the study was obtained and documented in the electronic data capture system. Both
institutional review boards recognized that oral informed consent for this kind of study is in
agreement with the local traditions in the study communities. Inclusion of minors in the study
required consent of one parent and assent of the child. The confidentiality of the data was
ensured through a coding process, and the project datasets did not contain personal identifying information.
The health Districts of Akoupé and Abengourou were co-endemic for LF, onchocerciasis
and STH and eligible for community-wide MDA with IVM plus ALB. Study villages had a
baseline Wuchereria bancrofti microfilaremia rate of at least 10% and an Onchocerca volvulus
nodule rate of at least 25%. Furthermore, villages eligible for the study had no previous MDA
for at least 12 months, were accessible by four-wheel drive cars, and expressed willingness to
participate in the community surveys. Among these eligible villages, four per health district
were randomly selected for inclusion in this cross-sectional study (S1 Table).

Study areas and population
The study areas are located in the forest zone of eastern Côte d’Ivoire (Fig 1, S1 Table). The
areas are characterized by a warm and humid climate. Study villages were rural agricultural
communities. The total population of Akoupé and Abengourou health Districts (sub-prefectures) is 80,000 and 175,000, respectively and the population size of the study villages ranged
between 500 and 3,200 residents. Anthelminthic drugs were available at local markets and at
District hospital pharmacy. Study participants from both districts reported similar access to
running water and latrines. However, people from Akoupé mentioned that they travelled
more frequently to the Abidjan metropolitan area. We have no evidence that the living condition have changed during the study period. Eligible for the study were individuals aged five
years or above and without any evidence of acute illness or severe chronic disease. Pregnant
women were not eligible to receive MDA. No school-based deworming was performed during
the study period.

Size of study population
The sample size was calculated for a two-sided test with a power of 80%, and an α-level of 0.05.
We estimated that prevalence of STH was around 20%. Thus, a total sample of at least 1,600
stools samples (800 per area) was required for impact assessment.

Demographics
Personal information such as name, sex, age was recorded in the electronic data capture system
and linked to the barcode. Study participants were examined for LF, onchocerciasis and a subset for STH in parallel. All laboratory samples were labelled by barcode only and results per
barcode were entered in a specific module. Later, the complete data set was linked and stripped
from personal identifying information before analysis.

Parasitological examination
STH testing was performed at baseline and at one year intervals after MDA. The last STH survey was performed one year after the last round of MDA in both treatment areas. In each
study area 1,200 stool containers (800 stool container + 50%) per area were distributed per
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Fig 1. Map of study sites in the health Districts of Abengourou and Akoupé in eastern Côte d’Ivoire. Geographic coordinates of each study site
were recorded using a hand-held global positioning system (GPS) receiver of the cell phone and Arc Map 10.2.1 (Environmental Systems Research
Institute Inc.; Redlands, USA) was used to generate the map of the study sites.
https://doi.org/10.1371/journal.pntd.0008642.g001
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year to potential study participants. Since about 2,000 subjects were examined for LF and
onchocerciasis, three out of five enrolled subjects received a stool container. Stool containers
were labeled with a barcode for each participant. Sometimes containers were also marked with
a sign or initials if many children of a family received a container to reduce the risk of a mixup. During the survey, subjects were instructed to produce stool on a piece of paper and transfer a walnut size piece into the container. The containers were collected during the day or at
the latest at the following morning, kept cool and transported to the field laboratory for immediate examination. Stool samples were tested with duplicate Kato-Katz smears on the same day
of collection [20]. Slides prepared from the same specimen were labeled with the patient ID
(barcode) and read within 60 min after preparation. Each of the two slides was examined by
one of the two microscopists using 40x magnification. Quality control of the slides was carried
out by a third experienced parasitologist. Ten percent of the slides were randomly selected and
reexamined. In cases of major disagreement between reading results, the entire series of slides
with differing results was reexamined. Reading results of the slides were recorded on a paper
form containing the barcode and results were subsequently entered into an electronic data
capture system. Analysis of 25 hookworm egg positive stool samples by qPCR [21], revealed
that all samples were positive for Necator americanus and negative for Ancylostoma duodenale.

Mass drug administration using ivermectin plus albendazole
The MDA was performed by the National Program for the Elimination of NTDs. Treatments
were initiated in 2014 and performed at month 0, 6,12, 18 and 24 (in Akoupé health District,
semi-annual MDA, 5 treatment rounds) and month 0, 12 and 24 (Abengourou health District,
annual MDA, 3 treatment rounds). Training sessions were held for health workers of the different study sites who assisted the national team. Local health workers were trained to administer the drugs and detect, manage and refer when necessary, adverse events following
treatment. Eligible inhabitants received directly observed oral treatment with IVM (0.2 mg/kg)
and ALB (a fixed dose of 400 mg). For dosing of IVM a dosing pole was used [22]. As recommended by WHO, an independent coverage survey was conducted in both Districts in 2017 by
an experienced social scientist [23].

Assessment of compliance to treatment
Data on compliance to treatment was recorded during the cross-sectional surveys, 12, 24 and
36 months after the start of MDA. The reported compliance was calculated on the base of the
proportion of the study population who reported during the follow-up to have swallowed once
(annual treatment area), or twice (semi-annual treatment area) in the previous year. In addition, an independent coverage survey according to WHO guidelines was conducted in Akoupé
about 3 months after the last follow-up survey/treatment in 2017 [24].

Data management and analysis
For the baseline survey and the first follow-up, demographic and laboratory data were
recorded and synchronized using Motorola cellular telephones (XT 720; Motorola, Chicago,
IL) before being sent to the server using the LinksSystem [19]. For later surveys, data were collected using EpiInfo for Mobile Devices App (Centers for Disease Control and Prevention,
Atlanta, GA); encrypted data were transferred to an Azure cloud server (Microsoft, Seattle
WA). For analysis, the data were downloaded as Excel files from the servers. Study participants
were classified into six age groups: �10 years, 11–20 years, 21–30 years, 31–40 years, 41–50
years, � 51 years. Intensity of infection was expressed as eggs per gram (epg). The mean infection intensity was computed using the arithmetic mean of infected subjects. Infection intensity
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was stratified into three categories (light, moderate and heavy) according to WHO thresholds
[25]. A. lumbricoides was defined between 1 epg to 4999 epg, 5000 epg to 49999 epg, and
�50000 epg. The species T. trichiura was defined as follows: 1 epg to 999 epg, 1000 epg to 9999
epg, and � 10000 epg. Ancylostoma spp. eggs were grouped between 1 epg and 1999 epg, 2000
epg and 3999 epg, and �4000 epg. S. mansoni was as follows: 1 epg to 99 epg, 100 epg to 399
epg, and �400 epg. Cross-sectional data were used to evaluate changes in infection rates and
intensities in study areas. Differences in infection rates were assessed by Chi-squared tests.
Change in infection intensity were assessed using Mann Whitney U tests.
In order to better compare results from the two Districts, mixed-effects logistic regression
models and mixed linear models were used to analyze hookworm presence and intensity,
respectively. Our statistical models included variables that corresponded to MDA treatment
(annual vs semi-annual), visit (baseline, year 1, year 2, year 3) and their interaction. Village
was treated as a random effect to account for intra-cluster correlation. All models were
adjusted for age and sex because these covariates are thought to be associated with hookworm infection. To account for infection prevalence differences between treatment groups
at baseline, we conducted an additional analysis where we analyzed follow-up data only (year
1, year 2, year 3) and adjusted for baseline prevalence in each village. We imputed mean
prevalence values for villages in each treatment area that were not included in the baseline
sample. p-values < 0.05 were considered significant. Statistical analyses were conducted
using STATA 12.00 software (Stata Corp., Texas, USA) and SAS version 9.4 (SAS Institute
Inc., NC, USA).

Results
Demographics and treatment reported compliance
For the assessment of STH we recruited 2,022 individuals at baseline (1,030 in the annual
MDA area and 992 in the semi-annual MDA area), 1,911 at the first follow up (1,112 vs 799,
respectively), 1,431 at the second follow up (748 vs 683, respectively), and 1,161 at the third follow up (531 vs 630, respectively). Between 48 and 84% of the subjects who received a stool container provided a stool sample suitable for analysis. The mean age of study participants in the
baseline survey was 31.2 years and 29.1 years for annual and semi-annual treatment areas,
respectively. The gender ratio (males per female) was 1.0 and 0.7, in annual and semi-annual
areas. The rate of compliance with treatment was assessed during the survey 6 to 12 months
after the last MDA. The mean of reported compliance was 65.2% in annual MDA area and
64.3% in semi-annual MDA area, with a range from 63.9% to 67.3% and from 62.1% to 66.2%,
respectively, over the period of study. However, no statistically significant difference was
observed between treatment areas at follow up 1 (p = 0.267), follow up 2 (p = 0.762), and follow
up 3 (p = 0.400). An independent compliance survey according to WHO guidelines in 2017
confirmed the results and found a mean rate of compliance of 71.3% in the semi-annual MDA
area.

Prevalence of soil-transmitted helminths
During the baseline survey (pre-MDA) eggs of four helminth species (A. lumbricoides, hookworm [N. americanus], T. trichiura and S. mansoni) were found in stool samples from Abengourou (annual MDA) and Akoupé (semi-annual MDA). At baseline the hookworm
prevalence was two times higher in the annual MDA area (23.9%) than in the semi-annual
area (12.4%). Prevalence estimates were very low for A. lumbricoides (0.8% and 0.2%), T. trichiura (0.6% and 0.8%) and S. mansoni (1.3% and 1.8%), in annual and semi-annual MDA
areas, respectively. Therefore, we focused on hookworm for all further analyses.
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Impact of MDA using combined ivermectin and albendazole on hookworm
Hookworm prevalence and intensity data are provided in Table 1. Analysis by age group
revealed a similar pattern of hookworm infection in both study areas, with low prevalence and
light intensity among children under 10 years, and higher prevalence and heavier intensity in
older participants (Fig 2). At baseline, the prevalence of moderate and heavy hookworm infections was 1.3% and 1.0% in the semi-annual and annual treatment areas, respectively, and
dropped to 0.4% and 0.0% at year 3. The prevalence of heavy and moderate hookworm infections was generally low, and only single cases were detected, especially at baseline (Fig 2). Over
three years of the MDA program, the infection was more rapidly reduced in adult subjects
from both annual and semi-annual MDA areas. Reduction of mean intensity of hookworm
infection was higher in females in the semiannual MDA area, but reduction of hookworm
prevalence was higher in males in the annual MDA area (Table 2).

Comparison of annual and semi-annual MDA
The crude prevalence of hookworm in the annual MDA area decreased significantly from
23.9% at baseline to 5.5% at year 3 (p <0.001). In the semi-annual MDA area, the crude prevalence of hookworm fell also consistently from 12.4% at baseline (12.4%) to 1.9% at year 3 (p <
0.001). The rate of decrease was comparable in both treatment areas. Over the three years of
the study, the mean intensity of hookworm eggs in infected subjects was reduced to about a
quarter (from 406.2 epg to 118.3 epg) in the annual MDA area (p = 0.017). In the semi-annual
Table 1. Crude prevalence and intensity levels of hookworm infection in annual (1X) and semi-annual MDA area (2X) from baseline to year 3.
Baseline

1st follow up

2nd follow up

3rd follow up

Reduction

Prevalence % (95% CI)

23.9* (21.3–26.5)

13.2 (11.2–15.2)

7.3 (5.5–9.2)

5.5* (3.5–7.4)

77

Arithmetic mean epg (95% CI)

406.2** (306.3–506.2)

260.4 (169.7–351.1)

305.2 (81.2–529.3)

118.3** (77.9–158.8)

70.9

Epidemiological parameter
Abengourou (1X)

Level of intensity
No n (%)

784 (76.12%)

965 (86.78%)

693 (92.65%)

502 (94.54%)

Light n (%)

236 (22.8%)

145 (13.04%)

53 (7.08%)

29 (5.46%)

Moderate n (%)

6 (0.6%)

1 (0.90%)

0 (0.0%)

0 (0.0%)

Heavy n (%)

4 (0.4%)

1 (0.90%)

2 (0.27%)

0 (0.0%)

Total N (%)

1030 (100%)

1112 (100%)

748 (100%)

531 (100%)

Prevalence % (95% CI)

12.4* (10.3–14.4)

7.5 (5.7–9.3)

2.6 (1.4–3.8)

1.9* (0.8–3.0)

85

Arithmetic mean epg (95% CI)

804.9*** (516.1–1093.7)

135.0 (80.4–189.6)

136.0 (82.7–189.3)

875.0*** (0.0–2064.0)

-8.7

Akoupé (2X)

Level of intensity
No n (%)

869 (87.6%)

739 (92.5%)

665 (97.1%)

618 (98.1%)

Light n (%)

110 (11.1%)

60 (7.5%)

18 (2.9%)

10 (1.5%)

Moderate n (%)

6 (0.6%)

0 (0.0%)

0 (0.0%)

1 (0.2%

Heavy n (%)

7 (0.7%)

0 (0.0%)

0 (0.0%)

1 (0.2%)

Total N (%)

992 (100%)

799 (100%)

683 (100%)

630 (100%)

CI, Confidence interval
N, Number of individuals analyzed
n, Number of individuals with a state of infection
�

, Baseline and 3rd follow up prevalences statistically different

��

, Baseline and 3rd follow up intensity statistically different
, Baseline and 3rd follow up intensity comparable

���

https://doi.org/10.1371/journal.pntd.0008642.t001
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Fig 2. Hookworm infection intensity stratified by age group in sentinel areas of an MDA program to eliminate LF
and onchocerciasis in eastern Côte d’Ivoire. (A), Akoupé health District with semi-annual MDA. (B), Abengourou
health District with annual MDA. The last re-examination was performed 12 months after the last round of MDA. B0:
Baseline, Y1: Year 1, Y2: Year 2, Y3: Year 3.
https://doi.org/10.1371/journal.pntd.0008642.g002

treatment area with lower prevalence of hookworm eggs at baseline, the intensity in infected
subjects did not change significantly (804.9 epg vs 875.0 epg, p = 0.216) because of the low
number of infected individuals.
Mixed logistic regression and mixed linear models were used for further analysis of hookworm presence and intensity. Results indicated that there were significant differences between
treatments, and that these differences varied according to follow-up visit (Treatment x Visit,
p = 0.018). Odds-ratio estimates indicated that the annual treatment had greater odds of hookworm presence at all of the follow-up visits (Table 3). However, the annual treatment area also
had a higher baseline prevalence than the semi-annual treatment area (model adjusted prevalence in Abengourou: 22.2% [95% CI: 13.3, 34.7], Akoupé: 9.2% [95% CI: 5.3, 15.3]) indicating
that differences between treatment groups may be driven by higher initial prevalence in Abengourou. In fact, after adjusting for baseline prevalence, only the year 2 follow-up visit indicated
a difference between treatments (model adjusted odds ratio: 2.26 [95% CI: 1.03, 4.98],
p = 0.043; Table 3).
Our analysis of hookworm intensity also indicated that treatment differences varied by follow-up visit (Treatment x Visit, p = 0.002). In contrast to the prevalence results, Akoupé had a
higher mean intensity (adjusted geometric mean: 276.9 epg [95% CI: 216.9, 354.2]) than Abengourou (adjusted geometric mean: 145.0 epg [95% CI: 121.7, 172.7]; p = 0.054) at baseline.
However, the number of infected subjects was lower in Akoupé and the confidence interval
was larger. In the first follow-up visit, Abengourou had higher hookworm intensity (adjusted
geometric means: 101.9 epg [95% CI: 82.6, 125.8] vs 65.1 epg [95% CI: 48.4, 87.6], p = 0.029),
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Table 2. Comparison of hookworm prevalence, mean intensity and intensity classes in infected male and female subjects by treatment area and year.
Parameter

Baseline

Year 1

Age
(Year)

Gender n (%)

AM
(epg)

L

M

Akoupé

�14

Male

13
(8.7)

329.5

8.7

0.0 0.0 7 (5.9) 219.4

Female

20
(12.7)

574.8

Male

36
(14.2)

Female

Akoupé
Akoupé

>14

Akoupé
Abengourou

�14

Abengourou
Abengourou

>14

Abengourou

H

n (%)

Year 2

Health
District

AM
(epg)

L

M

H

n (%)

5.9

12.0 0.0 0.7 5 (4.0) 81.6

4.0

835.7

12.2 1.2 0.8 33
(11.5)

108.7

11.5 0.0 0.0 10
(5.3)

54
(12.5)

984.0

10.9 0.7 0.9 15
(5.6)

171.2

5.6

Male

46
(30.9)

240.3

30.2 0.7 0.0 40
(20.9)

205.2

20.9 0.0 0.0 15
(7.5)

Female

21
(17.5)

209.7

17.5 0.0 0.0 17
(8.4)

346.6

8.4

Male

90
(24.3)

414.5

23.8 0.0 0.5 55
(15.1)

303.0

14.5 0.3 0.3 24
(10.8)

Female

89
(22.8)

530.0

21.0 1.3 0.5 35
(9.9)

214.6

9.9

Year 3
AM
(epg)

L

M

0.0 0.0 4 (2.2) 151.7

2.2

0.0 0.0 1
(0.5)

12

0.5 0.0 0.0

0.0 0.0 3 (2.3) 96.0

2.3

0.0 0.0 6
(4.3)

1622.0

2.9 0.7 0.7

5.3

0.0 0.0 3
(1.6)

140.0

1.6 0.0 0.0

0.6

0.0 0.0 2
(1.7)

168.0

1.7 0.0 0.0

451.2

7.0

0.0 0.5 14
(8.3)

93.4

8.3 0.0 0.0

0.0 0.0 7 (3.9) 222.9

3.9

0.0 0.0 3
(2.4)

232.0

2.4 0.0 0.0

10.8 0.0 0.0 9
(6.3)

100.0

6.3 0.0 0.0

5.4

176.0

3.1 0.0 0.0

163.2

0.0 0.0 1 (0.6) 36

121.5

0.0 0.0 9 (6.1) 616.0

H

n (%) AM
(epg)

0.0 0.7 3
(3.1)

L

M

H

N, Number of individuals tested by Kato-Katz
n, Number of infected individuals
L, Light infection
M, Moderate infection
H, Heavy infection
epg, egg per gram of faeces
AM, Arithmetic Mean
https://doi.org/10.1371/journal.pntd.0008642.t002

but the mean intensities between treatment areas were not significantly different in subsequent
follow-up visits (p = 0.871 for year 2 and p = 0.258 for year 3).

Discussion
A goal of the WHO is to control STH and reduce the prevalence of moderate and heavy infections below 1%. This may eliminate STH infections as a public health problem and possibly
break transmission [26]. A key tool to achieve this goal is preventive chemotherapy. In the current study, LF and onchocerciasis are co-endemic in the study areas and a combination of
IVM with ALB is used for MDA as part of the national programs to eliminate LF and
Table 3. Mixed logistic regression analysis for annual (Abengourou) vs semi-annual (Akoupé) treatment comparisons at each follow-up visit after model adjustment for baseline prevalence. The odds ratio (OR) of the semi-annual
treatment group was calculated relative to the annual treatment group.
Not adjusted for baseline prevalence
Visit

Adjusted for baseline prevalence

OR (95% CI)

p

OR (95% CI)

p

Year 1

3.65 (1.51, 8.81)

0.004

1.06 (0.53, 2.12)

0.871

Year 2

7.58 (2.79, 20.57)

< 0.001

2.26 (1.03, 4.98)

0.043

Year 3

5.87 (2.03, 16.94)

0.001

2.0à (0.81, 4.9)

0.131

OR, Model-adjusted odds ratio
CI, Confidence interval
p, P-value
https://doi.org/10.1371/journal.pntd.0008642.t003

PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008642 September 25, 2020

10 / 15

PLOS NEGLECTED TROPICAL DISEASES Impact of mass drug administration for Lymphatic Filariasis and Onchocerciasis on Hookworm

onchocerciasis. IVM and ALB is one of the most efficacious drug combinations for hookworm
with average cure rates of 84% and egg reduction rates of 95% [27]. Therefore, IVM plus ALB
provided for LF and onchocerciasis elimination should also reduce STH, but little field data
have been published to quantify this effect on the community level [15]. Indeed, this may be
the first community-based study that measured the impact of annual and semi-annual MDA
for LF on STH in West Africa.
In our study, the self-reported compliance recalled during the next survey 6 to 12 months
after MDA in both treatment areas was sometimes lower than the 65% target for LF elimination programs [21]. However, an independent coverage survey [C. Comoe-Coffie, pers.
comm.] using a standardized questionnaire [23] documented a compliance rate of 71.3% in
our semi-annual area. It is possible that a proportion of subjects questioned in the independent
survey may have confused administration of IVM and ALB with another type of drug swallowed. However, it is more likely that the low compliance rate in our survey was caused by a
lack of accurate recall 6 to 12 months after MDA. A study performed in nine communities in
Kebbi State, Nigeria indicated that it is difficult to achieve 65% compliance during annual
MDA with IVM and ALB [28]. However, studies from other regions showed that it is feasible
to achieve high compliance rates over several rounds of MDA [29]. High compliance rates are
crucial for successful intervention and previous studies identified a number of challenges that
vary widely between settings and rounds of MDA [30–32].
Our results showed that MDA using IVM combined with ALB to eliminate LF and onchocerciasis had a strong impact on hookworm prevalence and intensity. While drug efficacy is
usually measured 2 to 4 weeks after treatment in a cohort, the impact of MDA on STH in this
study was assessed one year following treatment in a cross-sectional approach. After three
years of community-wide MDA, hookworm prevalence dropped from 23.9% to 5.5% and
from 12.4% to 1.9%, with reductions of 77% and 85% in the annual and semi-annual treatment
areas, respectively. These results are in line with cure rates of about 80% determined by metaanalysis of a number of clinical trials [27, 33, 34]. Although several computer modeling studies
predict the potential impact of community-wide MDA on hookworm prevalence [35, 36], field
observations from Africa are scarce. Our logistic regression analysis results indicated that,
after adjusting for differences in baseline prevalence, we were able to detect a difference
between both treatment regimens at only one of the three follow-up visits. However, it has to
be taken into account that only the Year 3 follow-up visit was done 12 months after the last
MDA round for both treatment groups, while in Year 1 and 2, evaluation was performed 12
months after the last MDA in the annual MDA group and 6 months after the last MDA in the
semi-annual MDA group.
Our results suggest that differences in hookworm prevalence reduction between the treatment areas are primarily driven by geographic differences and baseline prevalence. The similar
effects of the different treatment regimens (5 vs 3 rounds of MDA) may be explained by the
life cycle of the parasite. Annual MDA may be sufficient to eliminate most hookworms as
infective larvae, adult worms, and eggs because the drugs are larvicidal, vermicidal, and ovicidal. Hookworm infection is caused by the penetration of infectious, free-living L3 larvae that
survive only a few months in the soil [37]. Moreover, the study was done in low and moderate
endemic settings. Therefore, the infection pressure may be relatively low and re-infections
may be efficiently prevented even with annual community-wide MDA. Semi-annual and
annual MDA reduced the prevalence of moderate and heavy infections to 0.4% and 0%,
respectively. Thus, the appropriate threshold (<1%) for successful control of hookworm as
defined by WHO was achieved by both MDA regimens. During the third follow-up, relatively
few subjects were hookworm positive, but some of them had a relatively high intensity of infection. This may be an indicator of non-compliance [38] rather than an indicator of heavy
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transmission in the study villages and may call for specifically targeting groups of subjects who
more likely to be non-compliant with MDA [39].
The present study had two principal limitations. The reported compliance with MDA was
sometimes lower than the WHO recommended coverage level (65% for LF elimination and
75% for STH control). This may impact the proper comparison between annual and semiannual MDA. The second limitation is that our cross-sectional study design did not randomly
select the villages within an health District, because selection of study villages was guided by
LF and onchocerciasis prevalence. It has to be considered that we did not repeat STH testing
of infected individuals 2–4 weeks after treatment to assess cure and egg reduction rates. Barriers that could prevent individuals to be continuously included in parasitological survey would
be the absence from the village, misunderstanding, and lack of information [40]. However, our
study was not designed to assess drug efficacy, but to measure impact of an intervention
(MDA for LF and onchocerciasis), and cross-sectional sampling was sufficient for this
purpose.
In conclusion, both annual and semi-annual community-wide MDA for LF elimination
with IVM and ALB over three years resulted in dramatic reductions in hookworm prevalence
in low and moderate endemic settings in eastern Côte d’Ivoire. Thus, annual MDA for LF
elimination appears sufficient for effective hookworm control in areas with low to moderate
baseline prevalence, and separate school-based deworming is not necessary in such areas.
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